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ABSTRACT 
EFFICACY OF INTRAVENOUS ONDANSETRON IN RELIEVING 
NAUSEA/VOMITING AND PRURITUS POST EPIDURAL 
 ADMINISTERED OPIOIDS IN THE OBSTETRIC PATIENT 
by Benjamin Stephen Butler 
December 2016 
One prominent side effect in the use of a neuraxial anesthesia is pruritus, with an 
incidence in the obstetric patient of 60-100% (Kumar & Singh, 2013).  Another side 
effect of an epidural placement is nausea and vomiting.  Nausea and vomiting occurs 
frequently during the progress of labor and is difficult to determine an incidence that is 
related to epidural opioid administration (Chestnut et al., 2014).   A review of literature 
was performed and established evidence that ondansetron is effective in reducing 
incidence of pruritus in intrathecal administered opioids for cesarean sections in the 
obstetric patient.  No literature was found concerning ondansetron reducing either 
incidence of nausea/vomiting or pruritus in post epidural administered opioids for 
obstetric patient.  A retrospective chart review was completed and statistical analysis 
concluded that in this sample ondansetron was not effective in reducing nausea/vomiting 
or pruritus in the obstetric population (Pruritus p = .195 and Nausea/Vomiting p = .844).  
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CHAPTER I - INTRODUCTION 
For the obstetric patient population, an epidural is an elective anesthetic procedure 
that is used to decrease the pain and discomfort.  Epidurals are in a classification of 
anesthesia termed neuraxial anesthesia.  The administration of a local anesthetic is often 
used in combination with an opioid to provide neuraxial analgesia.  According to 
Chestnut et al. (2014), “neuraxial analgesia is the only form of analgesia that provides 
complete analgesia for both stages of labor” (p. 457).  The epidural is placed either by the 
anesthesia provider and it is the responsibility of the anesthesia provider to care for the 
patient until the epidural is discontinued when the obstetric patient delivers her baby.  
The anesthesia provider is responsible for ensuring patient safety and managing any 
potential side effects.  One prominent side effect in the use of a neuraxial anesthesia is 
pruritus, with an incidence in the obstetric patient of 60-100% (Kumar & Singh, 2013).  
Another side effect of an epidural placement is nausea and vomiting.  Nausea and 
vomiting occurs frequently during the progress of labor and is difficult to determine an 
incidence that is related to epidural opioid administration (Chestnut et al., 2014).  These 
side effects are not life-threatening but they are undesirable and a discomforting effect of 
neuraxial administration of opioids. 
Background 
In the majority of health care facilities a protocol is established to help alleviate 
the effects of nausea/vomiting and pruritus.  Currently there is no guideline endorsed by 
the American Society of Anesthesiologists (ASA) for these treatments.  Treatment is 
warranted by patient condition and the preference of the anesthesia provider.  The 
medications ordered for current treatments are not always effective in relieving the 
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patient of the pruritus.  A common first step intervention used in current treatments is the 
administration of diphenhydramine.  This medication inhibits the release of histamine but 
not all neuraxial administered opioids release histamine and the patient may still 
complain of pruritus. 
Ondansetron is a serotonin (5HT-3) antagonist that is approved by the Food and 
Drug Administration (FDA) for treatment of nausea and vomiting. Chestnut et al. (2014) 
indicate that, “prophylactic administration of ondansetron 4 to 8 mg has been shown to 
have better antiemetic profile in the first 24 hours after intrathecal and epidural opioid 
administration when compared with a placebo” (pp. 642-643).  Ondansetron also has 
been shown to help alleviate the pruritic side effect of neuraxial administered opioids and 
does not have the sedative effects commonly seen with diphenhydramine.  The exact 
mechanism of action for the reduction of pruritus from ondansetron is unknown.   
Significance 
Starting in January of 2016, the anesthesia department of a southeastern 
Mississippi healthcare facility created a four person epidural team consisting of all 
CRNAs that assumed the placement and management of epidurals in the obstetric patient.  
It was previously performed by the obstetric physicians.  Currently in practice, one 
CRNA is administering 4mg IV ondansetron within 5 minutes after placement of an 
epidural. 
Needs Assessment 
Osterman and Martin (2011) published in the National Vital Statistics Report that 
overall, 61% of women who had a single birth in a vaginal delivery in 2008 received 
either spinal or epidural anesthesia.  The Mississippi State Department of Health 
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(MSDH), Office of Public Health Statistics (2015) indicate that in 2014 there were a total 
of 38,735 live births.  If the assumption that 61% of those births were a vaginal delivery 
that received either spinal or epidural anesthesia, then approximately 23,628 live births 
were performed with the assistance of neuraxial anesthesia in the year 2014.  To further 
that the MSDH reported each county of Mississippi’s live births, Forrest County had 
1,038 births.  Assuming that 61% received neuraxial anesthesia for vaginal birth, roughly 
633 live births in Forrest County were performed with aid of neuraxial anesthesia.  This 
number of obstetric patients that may have the potential side effect of nausea/vomiting 
and/or pruritus from opioid administration via epidural or spinal anesthesia offers an 
assumption of significance to provide the utmost care. 
Overview of Literature Review 
The obstetric patient that has received a neuraxial analgesic deserves to have 
anesthesia care that is based on evidence based practice.  The focus of the literature 
review is to research the administration of ondansetron intravenously in preventing 
nausea/vomiting and reduce the incidence of pruritus.  The literature review is key to 
establishing the best evidence based practice to implement a change in practice. 
 PICO, Problem Statement, and Purpose 
Will the administration of IV ondansetron to the obstetric patient that has received 
opioids via an epidural reduce the incidence of nausea/vomiting and pruritus?  The 
administration of IV ondansetron within five minutes of successful epidural placement to 
the obstetric patient that has received opioids via an epidural will reduce the incidence of 
nausea/vomiting and pruritus in the setting of a southeast Mississippi health facility that 
has the highest amount of deliveries in the area.  This is the PICO statement and will be 
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the focus of the doctoral project. The purpose of this project was to determine the 
efficacy of intravenous ondansetron in reducing the incidence of nausea/vomiting and 
pruritus post epidural administered opioids in the obstetric patients.  Efficacy, in this 
project, was defined as the overall effectiveness of ondansetron to relieve or reduce the 
incidence of nausea/vomiting and pruritus in this patient population.  Comparison will be 
made between no administration of ondansetron 5 minutes after epidural placement and 
the administration of ondansetron within 5 minutes of epidural placement.  One member 
of the anesthesia team is using 4mg ondansetron IV within five minutes of epidural 
placement, the project will look at the efficacy of ondansetron in reducing epidural-
induced nausea/vomiting and will focus on ondansetron as an alternative medication for 
the relief of pruritus.  Pruritus is not life-threatening but it can be very frustrating and 
burdensome to the patient and may decrease overall patient satisfaction.  The effect may 
increase in intensity so that it disturbs the patient’s sleep.  By determining the efficacy of 
ondansetron in preventing nausea/vomiting and an added benefit of reducing the 
incidence of pruritus, a practice change can be made to provide future obstetric patients 
with the best evidenced based care. 
Doctor of Nursing Practice (DNP) Essentials 
This project met all eight DNP essentials as described in Appendix A.  The two 
essentials that were most represented in this project were essentials III and VI.  Essential 
III, Clinical Scholarship and Analytical Methods for Evidence-Based Practice, was 
demonstrated by using analytic methods to critically appraise existing literature on 
ondansetron reducing nausea/vomiting and/or pruritus in the obstetric patient, designed 
and implemented a process to evaluate the outcomes of current practice, then evaluated 
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quality improvement methodologies, performed research methods to collect appropriate 
data, inform, analyze, and the identify gaps, if any, in current practice.  Essential VI, 
Interprofessional Collaboration for Improving Patient and Population Health Outcomes, 
was demonstrated by employing effective communication and collaborative skills with 
the information technology (IT) department.  Electronic patient information charting 
(EPIC) was utilized for data collection and in the development and implementation of 
change in the health care system.  Collaboration with the IT department was vital in the 
inclusion and exclusion of criteria of data that is presented in Chapter III.  
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CHAPTER II – REVIEW OF LITERATURE 
A comprehensive review of literature was performed to locate information 
regarding the use of the drug ondansetron to reduce incidence of pruritus in obstetric 
patients receiving intrathecal opioids.  The search consisted of multiple databases 
accessed through the University of Southern Mississippi’s (USM) online catalogue.  The 
databases used were Ovid, Cochrane Library, Pubmed, CINAHL, and Ebscohost.  The 
search terms and MeSH terms used were ondansetron, Zofran, pruritus, nausea, obstetric, 
and epidural.  All of these search terms were used interchangeably and in different 
combinations for advanced searches that would result in a desired article.  Searches were 
limited to full text within the past 8 years.  Inclusion criteria were that the article must be 
written in English and must be relevant to the efficacy of ondansetron in reducing 
neuraxial-induced pruritus and nausea.  Exclusion criteria were any articles not written in 
English, which were not within the past 8 years, and were not relevant to the proposed 
topic of study.  A total of 136 articles resulted from this and 11 articles were used after 
omitting ones based on relevance or criteria. 
Cesarean Sections 
A prospective, randomized, double-blinded and placebo controlled study by Koju, 
Gurung, and Dongol (2015) was conducted over a 5 month period with 50 healthy 
parturients who were undergoing caesarean section under spinal anesthesia.  The patients 
were randomly categorized into placebo group and treatment group.  Twenty five 
received a placebo, 2ml of normal saline, and the treatment group of 25 received 4mg of 
ondansetron.  Each group was administered their respective dose 30 minutes prior to 
injection of intrathecal morphine.  Pruritus and post-operative nausea and vomiting 
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(PONV) scores were observed 24 hours after the administration of intrathecal morphine. 
Statistical analysis was done using chi-square test.  The placebo group experienced a 
significant increased incidence, severity, and need for treatment for pruritus than 
compared to the treatment group (88% vs 16% p< 0.001), and in both groups no 
participant required any additional medication to treat the pruritus (Koju et al., 2015).  
This result demonstrates ondansetrons efficacy on reducing pruritus with neuraxial 
morphine.  The study was limited to one type of 5HT-3 antagonist with a fixed dose; 
however, it efficiently shows that pruritus can be managed by the administration of 4mg 
IV ondansetron 30 minutes prior to morphine injected intrathecally.  In addition, the risk 
of PONV in the placebo group was increased compared to the treatment group (56% vs 
8%, p< 0.001) (Koju et al., 2015). 
Randomized, double-blind study by Gulhas et al. (2007), was aimed to compare 
the effectiveness of lornoxicam and ondansetron for the prevention of intrathecal 
fentanyl-induced pruritus in patients undergoing c-section.  One hundred and eight 
parturients ASA I-II status were given neuraxial analgesia by a combination spinal-
epidural (CSE) technique.  The CSE was performed and all participants received 25mcg 
of Fentanyl and 12mg hyperbaric bupivacaine.  Three groups were established, group L 
received 8mg IV of lornoxicam, group O received 8mg IV of ondansetron, and group P 
which received 2ml of normal saline, each group had 36 participants.  A Chi-square test 
was performed and results from 4 hours until 12 hours postoperatively, the incidence of 
pruritus was significantly lower for group O when compared to that in group L and group 
P (p < 0.05), also the number of patients experiencing no pruritus was significantly 
higher in group O than compared to the other groups (Gulhas et al., 2007, p. 161). 
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Dong, Soon, Ja-Young, Jae, and Ki (2007), looked at the effectiveness of epidural 
administration of ondansetron, rather than intravenously, to reduce pruritus in elective 
cesarean deliveries.  An animal study was performed on rats first to test for any 
neurotoxic side effects of ondansetron administered intrathecally.  Upon dissection of the 
spinal cord of the rats, there was no specific morphological or histological changes noted.  
Eighty patients undergoing cesarean delivery consented and participated in this study.  
Forty patients received ondansetron through an epidural (EP) and the remaining forty 
received the medication intravenously (IV).  The incidence of pruritus was significantly 
lower in the EP group (22.5% and 15%) than the IV group (55% and 30%) at 24 and 48 
hours post-operatively (p < 0.05) (Dong et al., 2007, pp. 683-687).  The administration of 
intrathecal administration of ondansetron needs to be evaluated further. 
In 2014, Kung et al. performed a prospective, randomized, double-blinded study 
to test the efficacy of prophylactic administration of ondansetron in reducing the 
incidence of intrathecal morphine-induced pruritus. Ninety participants undergoing 
cesarean section were randomized into three groups: placebo group (PLAC), treatment 
group (TREAT), or prophylactic group (PROPH). The patients all received the same dose 
of spinal anesthetic which included both 25 mcg of fentanyl and 250 mcg of morphine.  
Two syringes were prepared as follows: PROPH group: syringe A: ondansetron 8mg 
(4ml); syringe B normal saline 4ml; TREAT group: syringe A: normal saline 4ml; 
syringe B: ondansetron 8mg (4ml); PLAC group: both syringes were 4ml of normal 
saline. Syringe A was administered immediately following the umbilical cord clamping 
and syringe B administered in the post-anesthesia care unit (PACU). A visual analog 
scale (VAS) was then used to assess nausea, pain, and pruritus in time increments of 30, 
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60, and 120 minutes after arriving to the PACU. The study was terminated before 
completion due to lack of statistical evidence from the interim analysis that showed no 
effect from ondansetron in relieving pruritus. Statistical analysis was performed by 
ANOVA with Bonferroni correction or Fisher’s exact test (Kung et al., 2014, pp. 222-
236). Limitations to this study were that it was stopped early, intrathecal fentanyl was 
used in addition to morphine which deviates from the title suggestion of treatment of 
morphine-induced pruritus, and ketorolac, an anti-inflammatory medication, was given 
post-operatively and may have helped with the decrease of pruritus. 
Other Populations 
A systematic review of 15 randomized control trials shows the efficacy of a 
prophylactic single intravenous bolus of 5HT-3 receptor antagonists, such as 
ondansetron, in reducing pruritus after neuraxial administration of opioids.  The 5-HT3 
receptor antagonists have been shown to decrease the incidence and the intensity score of 
pruritus, primarily when morphine is used as the neuraxial opioid and suggested a 
decrease in the treatment of pruritus (Kumar & Singh, 2013).  The systematic review did 
not suggest that the 5HT-3 receptor antagonists was effective in reducing the incidence of 
pruritus after the injection of neuraxial lipid-soluble opioids, such as fentanyl. 
A double blind randomized case-control study was done by Jahanbakhsh, Fathi, 
and Bazyar (2014) to appraise the effects of ondansetron in preventing pruritus from 
intrathecal fentanyl in the orthopedic patient.  One hundred and seven participants were 
randomly assigned to the case group, which received 8mg of ondansetron IV, and 100 
randomly assigned to the control group, which received 4ml of normal saline.  After 
intrathecal fentanyl administration of 25mcg, the patients were evaluated at 5, 10, 30, 60 
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minutes and then hourly up to 6 hours for any side effects.  The presence, severity, and 
location of pruritus were also evaluated after 2 and 6 hours.  The data was analyzed using 
Kolmogorov-Smirnov test, student t-test, Mann–Whitney U, chi-square test, Fisher exact 
test, and Spearman linear correlation coefficient (Jahanbakhsh et al., 2014). The results 
were that the incidence of pruritus was 60% in the control group and 34% in the case 
group (Jahanbakhsh et al., 2014).  Pruritus among the participants was most prevalent at 
the injection site of fentanyl; however, the administration of ondansetron decreased 
pruritus at the injection site (Jahanbakhsh et al., 2014).  Some of the case group still 
experienced severe pruritus.  The phenomenon of neuraxial induced pruritus is 
undetermined and further studies must be performed to understand its true exact 
mechanism of action. It should be noted that these participants were undergoing 
orthopedic procedures, not an obstetric procedure, but the results are still promising in 
that it establishes a reduction of fentanyl-induced pruritus. 
Review of Literature Conclusion 
The review of literature has provided evidence that ondansetron is effective in 
reducing the incidence and the severity of pruritus associated with intrathecal 
administered opioids.  There was minimal literature on ondansetron and epidural use, the 
literature was older than eight years and was not used.  The review of literature states 
ondansetron to be a safe and effective alternative to treat intrathecal opioid-induced 
pruritus in the cesarean population and also in other patient populations. 
Theoretical Framework 
The theoretical framework that would best fit this study is the Model for Change 
to Evidence Based Practice developed and introduced by Rosswurm and Larrabee (1999).  
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The model framework involves six steps which are: 1.) assess need for change in 
practice; 2.) link problem with interventions and outcomes; 3.) synthesize best evidence; 
4.) design a change in practice; 5.) implement and evaluate the practice change; and 6.) 
integrate and maintain the change (Rosswurm & Larrabee, 1999).  The overall goal of 
this study is to implement a new protocol based on the best evidence-based practice.  By 
using the framework established by Rosswurm and Larrabee it will allow for a structured 
model to provide a change in practice in reducing the incidence of nausea/vomiting and 
pruritus with neuraxial administered opioids in the obstetric patient. 
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CHAPTER III  - METHODOLOGY 
For the obstetric patient population, the epidural is an elective anesthetic 
procedure that is used to decrease the pain and discomfort.  One prominent side effect to 
the use of an epidural is pruritus, with an incidence in the obstetric patient of 60-100% 
(Kumar & Singh 2013).  Ondansetron, an anti-emetic, has been shown to decrease the 
incidence of pruritus in the review of literature.  The next sections will present the 
proposed method design, data collection, and statistical analysis that will be used so that 
the necessary information to determine if this alternative treatment would be beneficial in 
decreasing the incidence of pruritus in the obstetric patients receiving epidural 
administered opioids. 
Population 
Inclusion criteria was the obstetric patient receiving an epidural opioid, are 
between the ages 20 and 40, English speaking, and vaginal delivery with an epidural.  
Exclusion included all of the obstetric patients that did not receive an epidural 
administered opioid and any patients that had a cesarean section.  Exclusion criteria also 
included obstetric patients that are younger than 20 years of age and older than 40 years 
of age, non-English speaking patients. 
Setting 
A 512-bed Level II trauma hospital in southeast Mississippi will be the facility in 
which the data is collected.  Retrospective chart analysis was used and the process of 
collecting the data was important in determining the efficacy of the study. 
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Design 
The study used a retrospective chart review coupled with quantitative statistical 
analysis to determine if the administration of IV ondansetron preemptively reduced the 
incidence of nausea and also reduce the incidence of pruritus following an epidural 
administered opioid.  Upon completion of the data collection process, an online sample 
size calculator was used to determine the sample size based on the number of the total 
population, the confidence level, and the confidence interval. 
A benefit of this study is that by using a retrospective chart analysis there were no 
patient interactions and no intervention performed.  Patient safety was advocated, 
meaning the patients used in the study will be at no risk for harm.  Observations were 
made for obstetric patients who had pruritus and/or nausea after an epidural. 
Data Collection 
Successful Institutional Review Board (IRB) approval from the selected health 
care facility and then IRB approval from the University of Southern Mississippi, access 
to patient’s electronic medical record was granted.  All data recovered from the medical 
record was de identified ensuring confidentiality.  The time period requested was 
composed of two parts.  The first part was to research from February 1, 2015 to August 
31, 2015, this was to collect and observe data when the obstetric physicians were in 
charge of epidural management.  The second part was from February 1, 2016 to August 
31, 2016, this was to collect and observe the anesthesia epidural management.  Data 
collection recorded which medication treatment was given, either ondansetron or any 
other medication used and then record the outcome of the treatment and determine the 
effectiveness, if any, of the medications 
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All data collection was stored and de-identified on a password protected personal 
computer, and data was disposed of by shredding any paper documents or deleted from 
computer six months after all graduation requirements have been met. 
Statistical Analysis 
A t-test can be applied to establish two groups are statistically different from each 
other.  The two groups can be classified as no administration of ondansetron and 
administration of ondansetron and observing the incidence of pruritus and/or nausea of 
the two groups.  Power analysis calculator provided on https://www.ai-
therapy.com/psychology-statistics/sample-size-calculator was used to estimate the 
appropriate sample size (AI-Therapy Statistics, 2016).  A one-tailed t-test, with 
independent groups, effect size of 0.6, significance level (α) of 0.05, and power of 0.8 
determined that a sample size of 72 (36 in each group) is sufficient to produce statistical 
evidence that the two groups are statistically different.  Additionally an odds ratio was 
utilized to determine the odds that a particular outcome will occur.  Administration of 
ondansetron can be a variable and the odds ratio can predict the odds that the outcome of 
decreased nausea/vomiting and pruritus can occur.  This can be further compared to no 
administration of ondansetron and determining the odds that the outcome decreased 
nausea/vomiting and pruritus can occur.  Based upon the significance level, the validity 
of the quantitative study was established and included in the project. 
Conclusion 
In conclusion, a retrospective chart analysis was used to determine the efficacy of 
ondansetron relieving pruritus and/or nausea compared to that of diphenhydramine in the 
obstetric patient that has received epidural administered opioids.  This methodology does 
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not place the patient’s safety and health at risk.  Inclusion criteria for the project was 
stated and there will be no breech in patient confidentiality.  Statistical analysis ultimately 
determined if the outcomes of collected data has validity and significant statistical 
evidence that ondansetron is more effective in preemptively reducing the incidence of 
nausea and vomiting and in addition reduce the incidence of epidural opioid-induced 
pruritus in the obstetric patient. 
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CHAPTER IV – ANALYSIS OF DATA 
Results 
A retrospective chart analysis was performed to identify the efficacy of 
ondansetron in reducing the incidence of pruritus post epidural administered opioids in 
the obstetric patient.  The software Electronic Patient Identification Chart (EPIC) was 
used to view the patient charts that met the inclusion criteria.  The facility was unable to 
offer the patient charts requested for February, 2015 to August, 2015.  The only available 
charts granted permission to review were from the dates of February 2, 2016 until August 
31, 2016.  A total of 605 (N=605) charts met the criteria and after further evaluation only 
a total of 24 (n=24) patients were administered ondansetron within the five minute time 
parameter as established in the data collection tool (Appendix D).  Additionally 581 
(n=581) patients were not administered ondansetron and used in the statistical analysis. 
Demographics 
Table 1  
 Demographics of Patients that Received Ondansetron 
Characteristics  
 
Number Percentage 
Delivery Method 
Vaginal 
 
24 
 
100 
Anesthetic 
Epidural 
 
24 
 
100 
Age 
Mean 
Range 
 
28.3 
21-39 
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All patient information was collected using EPIC and was de-identified on a 
personal password protected computer.  No identifiable patient information was removed 
from the facility.  The patient demographics are listed in Table 1, and illustrate that the 
patients were within the parameters of the inclusion criteria. 
Relevant Results 
Of the 24 patients that received ondansetron five minutes after epidural placement 
only one patient experienced pruritus and required administration of 25mg 
diphenhydramine IV.  The patient received the medication 7 hours post epidural 
placement.  The incidence of pruritus in those patients that received ondansetron was 
4.17%.  In addition, four patients also needed additional treatment for nausea/vomiting.  
One patient received 12.5mg Phenergan IV and three patients received another dose of 
4mg ondansetron IV.  The average time onset of nausea/vomiting in these four patients 
was 9 hours post epidural placement. The incidence of nausea/vomiting in this group was 
16.67%. 
It was observed that in the group of 581 patients involved in this study that did not 
receive ondansetron within 5 minutes of epidural placement only 6 patients required 
treatment of pruritus with diphenhydramine, 5 patients received 25mg orally and one 
patient received 25mg IV, and one patient experienced severe pruritus and required a 
total of four doses of 25mg diphenhydramine orally. The other five in the group only 
required one dose.  The group that did not receive ondansetron within 5 minutes of 
epidural placement had an incidence of pruritus of 1.03%.  The average time onset of 
pruritus was 8.34 hours after epidural placement.  It was noted that in this group 105 
patients experienced nausea/vomiting. This is an incidence of 18.07%.  The average time 
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onset of nausea/vomiting in these patients was 4.49 hours.  By doing simple probability, 
based on this sample group, it was determined that the odds of having pruritus are 4.18 
times greater for obstetric patients who did receive ondansetron.  This was attributed to 
the fact that the ondansetron group had a pruritus incidence of 4.17% and compare that to 
the no administration of ondansetron group which had an incidence of 1.03%.  It was also 
determined that the odds of having nausea/vomiting are 1.1 times greater for obstetric 
patients who did not receive ondansetron.  Based on this sample size of the population 
there is an increased odds of having pruritus with pre-treatment of ondansetron.  There 
was however a very small increased odds of having nausea/vomiting with no pre-
treatment of ondansetron. 
Data Analysis 
The initial statistical analysis test was originally a one-sided t test.  This was 
further evaluated and was determined that this test would be insufficient and a forward 
logistic regression along with an odds ratio test would be the optimal test to perform.  
Forward logistic regression was conducted to determine if the independent variable 
(ondansetron) is a predictor of pruritus and nausea/vomiting in obstetric patients that 
received opioids via an epidural. 
Pruritus 
Regression results indicated that the overall model fit of the predictor 
(ondansetron) was reasonably good (-2 Log likelihood = 75.128) and was not statistically 
reliable in distinguishing between variables [Independent variable (ondansetron) and 
dependent variable (pruritus)] [x²(1) = 1.222, p = .269].  The model is accurate in 
classifying 98.8% of the participants.  Regression coefficients are presented in Table 2.  
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Wald statistics indicated that ondansetron did not significantly predict pruritus.  Odds 
ratio for the variable indicated very little change in the likelihood of patient experiencing 
pruritus. 
Table 2  
Regression Coefficients for Pruritus 
 B Wald df p Odds Ratio 
Ondansetron -1.427 1.681 1 .195 .228 
Constant -3.135 9.422 1 .002  
 
Nausea/Vomiting 
Regression results indicated that the overall model fit of the predictor 
(ondansetron) was debatable (-2 Log likelihood =573.669) and was not statistically 
reliable in distinguishing between variables [Independent variable (ondansetron) and 
dependent variable (nausea/vomiting)] [x²(1) = .039, p = .844].  The model correctly 
classified 81.8% of the cases.  Regression coefficients are presented in Table 3.  Wald 
statistics indicated that ondansetron did not significantly predict nausea/vomiting.  Odds 
ratio for the variable indicated very little change in the likelihood of patient experiencing 
nausea/vomiting. 
Table 3  
Regression Coefficients for Nausea/Vomiting 
 B Wald df p Odds Ratio 
Ondansetron .110 .039 1 .844 .894 
Constant -1.609 8.634 1 .003  
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Data Evaluation 
The overall purpose of this project was to determine if administration of 
ondansetron within five minutes of successful placement of an epidural would decrease 
incidence of nausea/vomiting and pruritus in the obstetric patient.  After evaluating the 
statistical analysis for this sample it was determined that the administration of 
ondansetron does not reduce the incidence of nausea/vomiting and pruritus in the 
obstetric patient post epidural administered opioids.  
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CHAPTER V – DISCUSSION 
Summary of Major Findings 
As stated in Chapter IV, after statistical analysis the administration of ondansetron 
within five minutes after epidural placement did not demonstrate significant statistical 
evidence that it decreases the incidence of nausea/vomiting and pruritus in the obstetric 
patient (Pruritus p= .195 and Nausea/Vomiting p= .844). 
Limitations and Barriers 
Limitations 
Limitations and barriers to this project were that it was an overall small sample 
size of patients that did receive ondansetron five minutes post epidural (n= 24).  The 
facility that was used in this project utilized an epidural infusion of Naropin 0.25% plus 
0.125mcg/ml of fentanyl at a rate of 10-18 ml/hour.  The current practice used in this 
facility does not use opioids in the loading dose of the epidural.  The only exposure of 
opioids the obstetric patient receives comes from the epidural infusion which is a 
minimal dose and a slow rate of infusion.  This is a limitation to this project because the 
patient is only exposed to a minimal concentration of opioids.  A history of post-
operative nausea/vomiting (PONV) in the obstetric patients was not observed and could 
have factored in the outcome.  Also, once the epidural was discontinued no more 
observations of nausea/vomiting and pruritus was recorded in the data collection.  There 
may have been more instances of nausea/vomiting and pruritus after the epidural was 
discontinued and could have had an impact on the statistical result. 
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Barriers 
A barrier to this project was that only one CRNA administered ondansetron 
within minutes post epidural, and in some instances the administration was after five 
minutes and did not meet the inclusion criteria and was excluded from the sample size. A 
technology barrier was present in that there was no electronic charting present for the 
requested dates of February 1, 2015 to August 31, 2015.  The facility used paper charting 
during those dates and were not able to provide these charts for the statistical analysis and 
could add more statistical validity to the project. 
Implications of Clinical Scholarly Project 
Based on the statistical analysis, the implications on nursing practice is that it 
provided anesthesia providers some evidence that ondansetron is not effective in 
decreasing the incidence of nausea/vomiting and pruritus post epidural administered 
opioids in the obstetric patient.  The results of this project will provide the obstetric 
patients with a more satisfying overall stay in the hospital which will enhance quality 
improvement.  For future studies, a needs assessment may need to done first to determine 
what the actual incidence of nausea/vomiting and pruritus is in post epidural administered 
opioids in the obstetric patient.  If there is a significant incidence (~ 50% or greater) of 
nausea/vomiting or pruritus the clinical question will ondansetron reduce the incidence 
on nausea/vomiting and pruritus can be utilized and further studied.  Further studies need 
to include a larger sample size to add more strength in the statistical analysis.  A 
recommendation of a longer time frame than five minutes to administer ondansetron post 
epidural can be further studied for any statistical difference.  Suggested future studies 
may want to observe if parity is a variable that can increase or decrease incidence of 
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nausea/vomiting and pruritus.  A history of PONV could be included in further studies to 
determine its impact on incidence of nausea/vomiting post epidural.  Finally, a study to 
determine if there is an increase in the incidence of nausea/vomiting and pruritus in either 
duramorph or fentanyl administered via epidural in the obstetric patient.  In the future, the 
author can perform either a pilot study or randomized control trial to add more statistical 
validity to this project.  
Dissemination of the findings was provided to the key stakeholders of the 
anesthesia department at the healthcare facility where the data was collected. Statistical 
analysis, interpretation of results, and future recommendations was presented.  
Dissemination of results and recommendations for future studies was also presented to 
students in the nurse anesthesia program at The University of Southern Mississippi.  In 
the future, the author can present findings to a state chapter or national anesthesia 
association. 
Conclusions 
The goal of this project was to determine the efficacy of intravenous ondansetron 
in reducing the incidence of nausea/vomiting and pruritus post epidural administered 
opioids in the obstetric patients.  A retrospective chart review was performed and 
statistical analysis revealed in this sample that ondansetron is not statistically significant 
in reducing either nausea/vomiting or pruritus.  This project can provide key stakeholders 
current evidence-based knowledge regarding nausea/vomiting and pruritus post epidural 
in the obstetric patient. 
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APPENDIX A – DNP Essentials 
Essential I: Scientific Underpinnings for Practice This capstone project described actions and 
advanced strategies to help alleviate the 
phenomena of post epidural administered opioid 
induced nausea/vomiting and pruritus. 
Essential II: Organizational and Systems 
Leadership for Quality Improvement and Systems 
Thinking 
This capstone project developed and evaluated 
care delivery that meet current and future needs of 
the obstetric patient who receives epidural 
administered opioids. 
Essential III: Clinical Scholarship and Analytical 
Methods for Evidence-Based Practice 
This capstone project used analytic methods to 
critically appraise existing literature on 
ondansetron reducing nausea/vomiting and/or 
pruritus in the obstetric patient, designed and 
implemented a process to evaluate the outcomes of 
current practice, then evaluated quality 
improvement methodologies, performed research 
methods to collect appropriate data, inform, 
analyze, and the identify gaps in current practice. 
Essential IV: Information Systems/Technology 
and Patient Care Technology for the Improvement 
and Transformation of Health Care 
This capstone project demonstrated the conceptual 
ability to develop and execute an evaluation plan. 
Essential V: Health Care Policy for Advocacy in 
Health Care 
This capstone project developed, evaluated, and 
provided leadership for health care policy and 
helped shape health care delivery to the obstetric 
patient who has received epidural administered 
opioids. 
Essential VI: Interprofessional Collaboration for 
Improving Patient and Population Health 
Outcomes- 
This capstone project employed effective 
communication and collaborative skills in the 
development and implementation of change in the 
health care system. 
Essential VII: Clinical Prevention and Population 
Health for Improving the Nation’s Health 
Dissemination of findings to state chapter or 
national anesthesia association upon completion of 
project  
Essential VIII:  Advanced Nursing Practice This capstone designed, implemented, and 
evaluated therapeutic interventions based on 
nursing science, to reduce the incidence of post 
epidural opioid-induced nausea/vomiting and 
pruritus in the obstetric patient population. 
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APPENDIX B – USM IRB Approval Letter 
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APPENDIX C – Facility IRB Approval Letter 
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APPENDIX D – Data Collection Tool 
 
       Age   Epidural 
assisted 
vaginal 
delivery   
Ondansetron 
administered within  
5 minutes of 
epidural   
   
Ondansetron not 
administered   
Any other 
medications used 
to treat N/V or 
pruritus  
Subject1                 
Subject2                 
Subject3                 
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APPENDIX E – Literature Matrix 
 
AUTHOR YEAR DESIGN FRAMEWORK SAMPLE FINDINGS 
Dong, W. H., Soon, 
W. H., Ja-Young, 
K., Jae, W. L., & 
Ki, K. J.  
2007 Not specified N/A (No 
Theoretical 
Framework used) 
N= 80 ASA I 
elective cesarean 
section  n=40 EP 
ondansetron n=40 
IV ondansetron 
The incidence of 
pruritus was 
significantly lower in 
the EP group (22.5% 
and 15%) than the IV 
group (55% and 30%) at 
24 and 48 hours post-
operatively (p < 0.05) 
Jahanbaksh, S. S., 
Fathi, M., & 
Bazyar, S.  
2014 double blind 
randomized case-
control study The 
data was 
analyzed using 
Kolmogorov-
Smirnov test, 
student t-test, 
Mann–Whitney 
U, chi-square 
test, Fisher exact 
test, and 
Spearman linear 
correlation 
coefficient.  
N/A (No 
Theoretical 
Framework used) 
N= 207 ASA I, II, 
III receiving lower 
extremity 
orthopedic surgery 
n= 107 ondansetron 
IV (case group) n= 
100 normal saline 
IV (control group) 
all receiving 25mcg 
of fentanyl 
intrathecally  
The results were that the 
incidence of fentanyl-
induced pruritus was 
60% in the control 
group and 34% in the 
case group  
Gulhas, N., Erdil, 
F. A., Sagir, O., 
Gedik, E., Togal, 
T., Begec, Z., & 
Ersoy, M. O. 
2007 randomized 
double blind 
study , chi-square 
test 
N/A (No 
Theoretical 
Framework used) 
N=108, ASA I, II, 
cesarean section, 
CSE 25mcg 
Fentanyl, n=36 
group L (8mg 
lornoxicam), n=36 
group O (8mg 
ondansetron), n=36 
group P (2ml 
normal saline) 
the incidence of pruritus 
was significantly lower 
for group O when 
compared to that in 
group L and group P (P 
< 0.05), also the number 
of patients experiencing 
no pruritus was 
significantly higher in 
group O than compared 
to the other groups 
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Koju, R. B., 
Gurung, B. S., & 
Dongol, Y 
2015 prospective, 
randomized, 
double-blinded 
and placebo 
controlled study 
chi-square test 
N/A (No 
Theoretical 
Framework used) 
N=50 ASA I, II 
caesarean section 
n=25 placebo (2ml 
normal saline) 
n=25 treatment 
(4mg ondansetron) 
receiving 0.2mg of 
morphine 
intrathecally 
The placebo group 
experienced a 
significant increased 
incidence, severity, and 
need for treatment for 
morphine-induced 
pruritus than compared 
to the treatment group 
(88% vs 16% P < 
0.001), and in both 
groups no participant 
required any additional 
medication to treat the 
pruritus  
Kumar, K., & 
Singh, S. I.  
2013 systematic review 
of 15 randomized 
control trials  
N/A (No 
Theoretical 
Framework used) 
Not specified The 5-HT3 receptor 
antagonists have been 
shown to decrease the 
incidence and the 
intensity score of 
pruritus, primarily when 
morphine is used as the 
neuraxial opioid and 
suggested a decrease in 
the treatment of pruritus. 
did not suggest that the 
5HT-3 receptor 
antagonists was 
effective in reducing the 
incidence of pruritus 
after the injection of 
neuraxial lipid-soluble 
opioids, such as 
fentanyl.  
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Kung, A. T., Yang, 
X., Li, Y., 
Vasudevan, A., 
Pratt, S., & Hess, P. 
2014 prospective, 
randomized, 
double-blinded 
study Statistical 
analysis was 
performed by 
ANOVA with 
Bonferroni 
correction or 
Fisher’s exact 
test.  
N/A (No 
Theoretical 
Framework used) 
N=90 ASA I, II n 
(PLAC)= 26, n 
(TREAT)= 32, n 
(PROPH)= 24 
undergoing 
cesarean section 
were randomized 
into three groups: 
placebo group 
(PLAC), treatment 
group (TREAT), or 
prophylactic group 
(PROPH). The 
patients all 
received the same 
dose of spinal 
anesthetic which 
included both 25 
mcg of fentanyl 
and 250 mcg of 
morphine.   
The study was 
terminated before 
completion when the 
interim analysis showed 
no effect. .  Limitations 
to this study were that it 
was stopped early, 
intrathecal fentanyl was 
used in addition to 
morphine which 
deviates from the title 
suggestion of treatment 
of morphine-induced 
pruritus, and ketorolac, 
an anti-inflammatory 
medication, was given 
post-operatively and 
may have helped with 
the decrease of pruritus  
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